Immix Biopharma (IMMX) Interest Expenses (2021 - 2022)
Quarterly results put Interest Expenses at $109.0 for Q2 2022, down 99.8% from a year ago — trailing twelve months through Mar 2023 was $109.0 (down 99.93% YoY), and the annual figure for FY2022 was $497.0, down 99.72%.
Immix Biopharma has reported Interest Expenses over the past 2 years, most recently at $109.0 for Q2 2022.
- Interest Expenses reached $109.0 in Q2 2022 per IMMX's latest filing, down from $388.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $53937.0 in Q3 2021 and bottomed at $109.0 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 12.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -332,000.00 |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 109.00 |
| Jun 30, 2022 | 109.00 |
| Mar 31, 2022 | 388.00 |
| Mar 31, 2022 | 388.00 |
| Dec 31, 2021 | 44,507.00 |
| Dec 31, 2021 | 44,507.00 |
| Sep 30, 2021 | 53,937.00 |
| Sep 30, 2021 | 53,937.00 |
| Jun 30, 2021 | 53,865.00 |
| Jun 30, 2021 | 53,865.00 |
| Mar 31, 2021 | 27,544.00 |
| Mar 31, 2021 | 27,544.00 |